Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04501705 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Apatinib in the Treatment of Recurrent Atypical/malignant Meningioma in Adults

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated October 15, 2024 (before its estimated August 31, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Study Identification, Study Status, Oversight, Conditionsv6
  2. 2 versions Re-verified since Feb 10, 2022, no change to tracked fieldsv4-v5
  3. Start date changed from estimate of Aug 2020 to Aug 18, 2020v3
  4. Site contact updatedv2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Apatinib mesylate may be an effective treatment for recurrent atypical/malignant meningioma. This prospective clinical study is now planned to verify the effectiveness and safety of apatinib mesylate in the treatment of relapsed atypical/malignant meningioma.
Trial Details
NCT Number NCT04501705
Lead Sponsor Beijing Sanbo Brain Hospital
Conditions
(from sponsor)		 Recurrent Atypical/malignant Meningioma
Related terms Meningioma
Enrollment 29 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov